--- title: "60 Degrees Pharmaceuticals, Inc. (SXTP.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/SXTP.US.md" symbol: "SXTP.US" name: "60 Degrees Pharmaceuticals, Inc." industry: "Pharmaceuticals" datetime: "2026-04-30T15:15:42.235Z" locales: - [en](https://longbridge.com/en/quote/SXTP.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/SXTP.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/SXTP.US.md) --- # 60 Degrees Pharmaceuticals, Inc. (SXTP.US) ## Company Overview 60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Exchange | US Market | | Website | [www.60degreespharma.com](https://www.60degreespharma.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: B > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-04-30T04:30:17.000Z **Overall: B (0.37)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 32 / 188 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: B #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 106.81% | | | Net Profit YoY | 6.69% | | | P/B Ratio | -0.68 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 4139757.16 | | | Revenue | 1409095.00 | | #### Multi Score Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 135.20% | A | | Profit Margin | -522.69% | E | | Gross Margin | 44.53% | B | | Revenue YoY | 106.81% | A | | Net Profit YoY | 6.69% | C | | Total Assets YoY | -6.83% | D | | Net Assets YoY | -14.55% | E | | Cash Flow Margin | 87.07% | C | | OCF YoY | 106.81% | A | | Turnover | 0.25 | D | | Gearing Ratio | 37.02% | B | ```chart-data:radar { "title": "Longbridge Financial Score - 60 Degrees Pharmaceuticals, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "106.81%", "rating": "" }, { "name": "Net Profit YoY", "value": "6.69%", "rating": "" }, { "name": "P/B Ratio", "value": "-0.68", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "4139757.16", "rating": "" }, { "name": "Revenue", "value": "1409095.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "B", "indicators": [ { "name": "ROE", "value": "135.20%", "rating": "A" }, { "name": "Profit Margin", "value": "-522.69%", "rating": "E" }, { "name": "Gross Margin", "value": "44.53%", "rating": "B" }, { "name": "Revenue YoY", "value": "106.81%", "rating": "A" }, { "name": "Net Profit YoY", "value": "6.69%", "rating": "C" }, { "name": "Total Assets YoY", "value": "-6.83%", "rating": "D" }, { "name": "Net Assets YoY", "value": "-14.55%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "87.07%", "rating": "C" }, { "name": "OCF YoY", "value": "106.81%", "rating": "A" }, { "name": "Turnover", "value": "0.25", "rating": "D" }, { "name": "Gearing Ratio", "value": "37.02%", "rating": "B" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.53 | 84/188 | - | - | - | | PB | -0.68 | 210/188 | - | - | - | | PS (TTM) | 2.94 | 76/188 | 5.55 | 4.25 | 2.25 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B | | 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B | | 03 | Roche (RHHBY.US) | A | B | B | D | B | B | | 04 | AstraZeneca (AZN.US) | A | B | C | D | B | B | | 05 | Novo Nordisk AS (NVO.US) | A | B | B | D | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-04-09T04:00:00.000Z Total Analysts: **2** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 2 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 1.60 | | Highest Target | 24.00 | | Lowest Target | 4.20 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SXTP.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SXTP.US/norm.md) - [Related News](https://longbridge.com/en/quote/SXTP.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SXTP.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**